Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.70 |
| ▸ | BCHE | P06276 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055052 | 0.95 | F2 (0.63) | F2BCHEMEN1TP53GAA | |
| SCHEMBL14075918 | 0.87 | APP (0.58) | F2BCHEMEN1KMT2A | |
| SCHEMBL14075895 | 0.86 | TSHR (0.54) | F2BCHEMEN1KMT2A | |
| SCHEMBL14075899 | 0.84 | BCHE (0.54) | F2BCHEMEN1TP53GAA | |
| SCHEMBL1413125 | 0.84 | FABP1 (0.67) | MEN1KMT2A | |
| SCHEMBL8082984 | 0.83 | MAPT (0.82) | F2BCHEMEN1TP53GAA | |
| SCHEMBL7316316 | 0.83 | F2 (1.00) | F2BCHEMEN1TP53GAA | |
| SCHEMBL28475529 | 0.82 | FABP1 (0.64) | MEN1KMT2A | |
| SCHEMBL11838896 | 0.81 | MAPT (0.84) | F2BCHEMEN1TP53GAA | |
| SCHEMBL7318445 | 0.81 | CXCR4 (0.72) | F2BCHEMEN1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | LIOTTA DENNIS C | 2008-09-18 | — | — | US | disclosed |
| WO-2008008852-A2 | CXCR4 ANTAGONISTS INCLUDING HETEROATOMS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227799-A1 | CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders | CXCL12, CXCR4, CXCR1 | F2 3871/4885BCHE 4819/4885MEN1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.